Showing 15 posts of 17 posts found.


Novartis’ Tafinlar/Mekinist combo improves five-year relapse-free survival in new Phase 3 data

September 17, 2020
Research and Development Novartis, Tafinlar, mekinist, melanoma

Novartis has unveiled promising new Phase 3 data for its combination of Tafinlar (dabrafenib) with Mekinist (trametinib) in the treatment …

NICE recommends Novartis combo as first-ever BRAF-targeted therapy for advanced post-surgery melanoma

September 17, 2018
Sales and Marketing Cancer, NICE, Novartis, Tafinlar, mekinist, melanoma, pharma

NICE has taken the decision to recommend the first ever first BRAF-targeted therapy for use on the NHS in England …


FDA approves Novartis combo in rare thyroid cancer subtype

May 8, 2018
Manufacturing and Production, Sales and Marketing Cancer, FDA, Tafinlar, mekinist, thyroid cancer

The FDA has announced its decision to approve the use of Novartis’ combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in …


Novartis combo expands into lung cancer with EU approval

April 4, 2017
Manufacturing and Production, Sales and Marketing NSCLC, Novartis, Tafinlar, mekinist

Novartis has announced that its Tafinlar (dabrafenib) and Mekinist (trametinib) drug combo has been approved by the European Commission (EC) …


Novartis says Phase II data for rare lung cancer showed overall response rate of 63%

June 7, 2016
Manufacturing and Production, Research and Development, Sales and Marketing ASCO, Novartis, Tafinlar, drug trial, lung cancer, mekinist

Swiss drugmaker Novartis (VTX: NOVN) said combination mid-stage trials for the drug to treat a rare and aggressive form of …

AZ image

AstraZeneca lung drug shines on

June 1, 2015
Sales and Marketing ASCO, AZD9291, AstraZeneca, MEDI4736, NSCLC, Tafinlar

AstraZeneca’s investigational drug AZD9291 is continuing to impress, with results announced at cancer conference ASCO building on its previous ‘unprecedented’ …

GSK melanoma drug sees quick NICE nod

September 18, 2014
Sales and Marketing Cancer, GSK, NICE, Tafinlar, Yervoy, dabrafenib, melanoma, skin cancer

NICE is recommending GlaxoSmithKline’s new melanoma treatment Tafinlar (dabrafenib) after the firm offered a discount for its medicine. In final …

GSK melanoma drugs beat rival in new study

July 18, 2014
Sales and Marketing GSK, Roche, Tafinlar, Yervoy, Zelboraf, mekinist, melanoma

GlaxoSmithKline’s new combination melanoma treatment has bested Roche’s established oncology drug Zelboraf when treating patients with the deadliest form of …

gsk image

Mekinist shown EU green light

July 7, 2014
Sales and Marketing CHMP, Cancer, GSK, Tafinlar, braf, mekinist, melanoma

The European Commission has given GlaxoSmithKline’s melanoma drug Mekinist the thumbs-up following a positive opinion in April from the European …

GSK and Novartis sign multi-billion dollar deal

April 23, 2014
Research and Development, Sales and Marketing GSK, Novartis, Tafinlar, lilly, merger, tykerb, vaccines

GlaxoSmithKline and Novartis are radically shaking up their businesses, starting up a joint venture while selling off major parts of …

gsk image

GSK to make ‘fundamental changes’

February 6, 2014
Sales and Marketing China, GSK, Tafinlar, Witty, q4, results

GlaxoSmithKline has pledged to make ‘fundamental changes’ to the manner in which it does business, looking at its interaction with …

Three new entries to Cancer Drugs Fund

February 5, 2014
Research and Development, Sales and Marketing CDF, Kadcyla, NHS, Tafinlar, UK, xofigo

Three drugs – Roche’s Kadcyla, Bayer’s Xofigo and GlaxoSmithKline’s Tafinlar – have been added to England’s Cancer Drugs Fund (CDF). …

GSK has Tafinlar ‘breakthrough’

January 15, 2014
Sales and Marketing Cancer, FDA, GSK, NSCLC, Tafinlar

GlaxoSmithKline is on a roll, with its cancer drug Tafinlar given breakthrough therapy designation by the FDA in lung cancer …

gsk image

FDA approves GSK cancer combo

January 14, 2014
Research and Development, Sales and Marketing FDA, GSK, Tafinlar, mekinist

US regulators have shown the green light to a combination of two GlaxoSmithKline skin cancer drugs, Mekinist and Tafinlar, to …

Latest content